Free Trial
LON:MXCT

MaxCyte (MXCT) Share Price, News & Analysis

GBX 350
+1.00 (+0.29%)
(As of 07/26/2024 ET)
Today's Range
340
356
50-Day Range
296
400
52-Week Range
180
430
Volume
969 shs
Average Volume
26,780 shs
Market Capitalization
£365.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MXCT stock logo

About MaxCyte Stock (LON:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
MaxCyte earnings: here's what Wall Street expects
MaxCyte Earnings Preview
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Business Services
CIK
N/A
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Net Income
£-36,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£44.05 million
Cash Flow
GBX 177.48 per share
Book Value
GBX 217 per share

Miscellaneous

Free Float
N/A
Market Cap
£365.89 million
Optionable
Not Optionable
Beta
1.07
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $484.7k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder
    Comp: $950.01k
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $514.26k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. David Sandoval
    Senior Vice President & General Counsel
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Ms. Jill Mayer
    Senior Vice President of Human Resources

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at GBX 352.50 at the start of the year. Since then, MXCT stock has decreased by 0.7% and is now trading at GBX 350.
View the best growth stocks for 2024 here
.

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO).

This page (LON:MXCT) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners